Enterprise Value
222.2M
Cash
23.56M
Avg Qtr Burn
-8.569M
Short % of Float
10.63%
Insider Ownership
31.01%
Institutional Own.
12.28%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Belapectin (GR-MD-02) Details Non-alcoholic steatohepatitis | Phase 2/3 Data readout | |
Belapectin (GR-MD-02) + keytruda Details Head and neck squamous cell carcinoma, Head and neck cancer | Phase 2 Initiation | |
Belapectin (GR-MD-02) Details Psoriasis | Failed Discontinued |